PUBLICACIONES

Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Source: Alberto Borobia Published on 2026-03-07
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Source: Alberto Borobia Published on 2026-03-07
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Source: Alberto Borobia Published on 2026-03-07
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Source: Alberto Borobia Published on 2026-03-07
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Source: Alberto Borobia Published on 2026-03-07
Combined Oral Contraceptive Drug-Drug Interaction Study With Ganfeborole, a New Anti-Tuberculosis Agent
Source: Alberto Borobia Published on 2026-03-07
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study
Source: Alberto Borobia Published on 2026-02-17
Genetic patterns related to von Willebrand factor: implications on the need for mechanical ventilation, severity, and death in COVID-19
Source: Alberto Borobia Published on 2026-01-26
The READI European project: Enhancing inclusivity in clinical research
Source: Alberto Borobia Published on 2025-11-17
Analgesic Effect of a Novel Intravenous Ibuprofen-Low-Dose Tramadol Combination: A Multimodal Approach to Moderate-to-Severe Postoperative Dental Pain
Source: Alberto Borobia Published on 2025-10-29
DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger
Source: Alberto Borobia Published on 2025-10-06
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial
Source: Alberto Borobia Published on 2025-03-04
The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19
Source: Alberto Borobia Published on 2025-01-29
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
Source: Alberto Borobia Published on 2025-01-14
Shaping current European mitochondrial haplogroup frequency in response to infection: the case of SARS-CoV-2 severity
Source: Alberto Borobia Published on 2025-01-09

Hospital Universitario La Paz

Servicio de Farmacología Clínica – UCICEC

Horario:

Lunes a Jueves 8.00-17.00

Viernes 8.00 - 15.00

Teléfono: 91 207 14 66

Fax: 91 207 13 84

Email: ucicec.hulp@salud.madrid.org